Novavax on Thursday tried to calm investors spooked by the delay of full approval of its COVID vaccine shot by U.S.

A new vaccine that combines flu and COVID-19 protection in one shot shows promising results, but the U.S. Food and Drug ...

FDA grants accelerated approval to Verastem's Avmapki Fakzynja for KRAS-mutated ovarian cancer; company plans $75 million funding for future developments.

In the wake of mass restructuring efforts across the Department of Health and Human Services, the FDA has missed yet another ...

Novavax posts $667 million in Q1 2025 revenue and $2.93 EPS, boosted by Sanofi payments and APA terminations; full-year ...

Novavax (NASDAQ:NVAX) pivots back to profitability after delivering a $666.7 million revenue haul in Q1surpassing estimates ...

Q1 2025 Management View CEO John Jacobs highlighted the shift in Novavax's corporate strategy over the past year, ...

The U.S. Food and Drug Administration said on Thursday all its centers will deploy artificial intelligence internally ...

Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ETCompany ParticipantsLuis Sanay - Vice President, Investor ...

The independent experts will meet on May 22 to discuss updates to the COVID-19 vaccine for the upcoming season.

The U.S. Food and Drug Administration has approved Verastem's combination therapy for patients with a type of ovarian cancer ...

Senior leaders at the FDA began pushing Moderna and Pfizer to file for full, formal approval of their COVID vaccines for ...